Abstract
In order to better explore the toxicity and the activity of high dose epirubicin (120 mg/m2, 3 weeks) we analyzed a population of 127 metastatic breast cancer patients, treated in a randomized clinical trial conducted to evaluate the cardioprotective effect of dexrazoxane against epirubicin induced cardiotoxicity. All the patients had a diagnosis of metastatic breast cancer, an ECOG performance status ≥2 and normal hematologic, renal, hepatic and cardiac function. No prior adjuvant chemotherapy including anthracycline was allowed. Epirubicin was given at the dose of 120 mg/m2 i.v. bolus every 3 weeks. One hundred twenty five patients were evaluable for toxicity and response. Seventeen patients (11%) had a complete response and 47 patients (37%) a partial response, for an overall response rate of 48%. The median progression free and overall survivals were 8.3 months and 18.3 months, respectively. Grade 3 and 4 leukopenia were observed in 8% and 7% of the patients, respectively. The most frequent nonhematological grade 3 toxicities were alopecia (87%), nausea and vomiting (16%), and mucositis (8%). Cardiotoxicity, defined as occurrence of congestive heart failure, decrease in resting left ventricular ejection fraction (L-VEF) to ≥45, or 20 EF units decrease from baseline L-VEF, was observed in 19% of the patients, after a median cumulative dose of epirubicin of 720 mg/m2 (range 120–1440). This study confirms in a large series of patients the activity of high dose epirubicin; however, the high incidence of cardiotoxicity requires a careful evaluation of cardiac risk factors before treatment.
Similar content being viewed by others
References
Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19: 197–228, 1993
Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9: 2148–2152, 1991
Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P et al: Drugs ten years later: epirubicin. Ann Oncol 4: 359–369, 1993
Carmo-Pereira J, Costa FO, Miles DW, Henriques E, Richards MA, Rubens RO et al: High dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study. Cancer Chemother Pharmacol 27: 394–396, 1991
Hickish T, Cunningham D, Haydock A, Coombes RC: Experience with intermediate dose (110- 120mg/m2) epirubicin. Cancer Chemother Rep 24: 61–64, 1989
Neri B, Pacini P, Algeri R, Lottini G, Rinaldini M, Tucci E et al: Conventional versus high dose epidoxorubicin as single agent in advanced breast cancer. Cancer Invest 11(2): 106–112, 1993
Fountzilas G, Skarlos D, Pavlidis NA, Makrantonakis P, Tsavaris N, Kalogera-Fountzila A, Giannakakis T, Beer M, Kosmidis P: High dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. Tumori 77: 232–236, 1991
Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 12: 3112–3120, 1996
Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 8th edition. Boston, MA, Little Brown, 1979
World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication, Geneva, Switzerland, WHO, 1979
Longo DL, Duffey PL, De Vita VT Jr, Wesley MN, Hubbard SM, Young RC: The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9: 2042–2051, 1991
Venturini M, Bruzzi P, DelMastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first line CEF regimen in patients with metastatic breast cancer. J Clin Oncol 14(3): 764–773, 1996
Armand JP, Hurteloup P, Bastit P: Epirubicin in advanced breast cancer, Preliminary results. Proc Am Soc Clin Oncol (abstr) 6: 66, 1987
Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, Olmos T, Pérez-Lopéz FR, Vassillopoulos P, Woods E and Coombes RC: Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol 15: 1988–1998, 1999
Habeshaw T, Paul J, Jones R, Stallard S, Steward M, Kaye SB, Soukop M, Symonds RP, Reed NS, Rankin EM: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 9: 295–304, 1991
Focan C, Andrien JM, Closon MT, Dicato M, Driesschaert P, Focan-Henrard D, Lemaire M, Lobelle JP, Longree L, Ries F: Dose response relationship of epirubicin-based firstline chemotherapy for advanced breast cancer: a prospective randomized trial. J Clin Oncol 11: 1253–1263, 1993
Bastholt L, Dalmark M, Gjedde S, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mourischen HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM: Dose-relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14(4): 1146–1155, 1996
Bonneterre J, Roché H, Bremond P, Kerbrat P, Namer M, Fumoleau P, Goudier MJ, Fargeot P, Bardonnet M, Marcillac I and Luporsi E: Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk nodepositive breast cancer patients. Proc Am Soc Clin Oncol 17: 124a, 1998
Rosti G, Albertazzi L, Ferrante P, Nicoletti P, Morandi P, Ban M, Macchi S, Monti G, Argnani M, Sebastiani L, Marangolo M: Epirubicin C G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients. Ann Oncol 6: 1045–1047, 1995
Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, Poplack DG, Oshughnessy JA: Pharmacokinetic of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86: 143–145, 1994
Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713–2721, 1996
Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699, 1995
Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510–2517, 1997
Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D: Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol 14(4): 1165–1172, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Michelotti, A., Venturini, M., Tibaldi, C. et al. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Res Treat 59, 133–139 (2000). https://doi.org/10.1023/A:1006394801389
Issue Date:
DOI: https://doi.org/10.1023/A:1006394801389